Evidence map›Paper›PMID 41199267›Full record

ArticleJournal of inflammation (London, England)2025

Lack of phospho-eIF4E worsens experimental colitis by inhibiting Treg suppressive activity.

François Santinon, Theodoros Papadopoulos, Meagan-Helen Henderson Berg, Paige McCallum, Madelyn J Abraham, Christophe Gonçalves, Vrinda Gupta, Natascha Gagnon, Noah Wirasinghe, Hsiang Chou and 4 more

Abstract read
In one paragraph

Article in Journal of inflammation (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

François Santinon *Division of Clinical and Translational Research, McGill University, Montreal, Québec, Canada. francoissantinon@gmail.com.
Theodoros Papadopoulos *Division of Clinical and Translational Research, McGill University, Montreal, Québec, Canada.
Meagan-Helen Henderson BergDivision of Clinical and Translational Research, McGill University, Montreal, Québec, Canada.
Paige McCallumDivision of Clinical and Translational Research, McGill University, Montreal, Québec, Canada.
Madelyn J AbrahamDivision of Clinical and Translational Research, McGill University, Montreal, Québec, Canada.
Christophe GonçalvesLady Davis Institute, Jewish General Hospital, Montréal, QC, Canada.
Vrinda GuptaDivision of Clinical and Translational Research, McGill University, Montreal, Québec, Canada.
Natascha GagnonLady Davis Institute, Jewish General Hospital, Montréal, QC, Canada.
Noah WirasingheDivision of Clinical and Translational Research, McGill University, Montreal, Québec, Canada.
Hsiang ChouLady Davis Institute, Jewish General Hospital, Montréal, QC, Canada.
Khashayar EsfahaniDivision of Clinical and Translational Research, McGill University, Montreal, Québec, Canada.
Margarita BartishDivision of Clinical and Translational Research, McGill University, Montreal, Québec, Canada.
Wilson H MillerDivision of Clinical and Translational Research, McGill University, Montreal, Québec, Canada. wilson.miller@mcgill.ca.
Sonia Victoria Del RinconDivision of Clinical and Translational Research, McGill University, Montreal, Québec, Canada. soniavictoria.delrincon@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPhosphorylation of eIF4E by MNK1/2 modulates protein synthesis by controlling the translation of specific mRNAs. Immune cells use the MNK1/2-eIF4E axis to adapt their gene expression in response to environmental cues, but its dysregulated activity promotes disease progression. While recent examples using cancer models have identified CD8

resultsWe found that Tregs isolated from mice deficient for phospho-eIF4E (expressing a serine-to-alanine mutation at S209) had a diminished ability to control CD4

conclusionsTaken together, these data highlight a role for phospho-eIF4E in Treg biology and in the control of inflammation. CLINICAL TRIAL NUMBER: Not applicable.

Identifiers

PMID41199267
PMCPMC12593924

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.